Adeno-associated virus (AAV) has emerged as a pivotal delivery tool in clinical gene
therapy owing to its minimal pathogenicity and ability to establish long-term gene expression …

On August 18, 2021, the American Society of Gene and Cell Therapy (ASGCT) hosted a
virtual roundtable on adeno-associated virus (AAV) integration, featuring leading experts in …

Replacing or editing disease-causing mutations holds great promise for treating many
human diseases. Yet, delivering therapeutic genetic modifiers to specific cells in vivo has …

Humans are exposed to nanoscopical nanobiovectors (eg coronavirus SARS-CoV-2) as
well as abiotic metal/carbon-based nanomaterials that enter cells serendipitously or …

BACKGROUND: Adeno-associated virus (AAV) has emerged as one of the best tools for
cardiac gene delivery due to its cardiotropism, long-term expression, and safety. However, a …

Adeno-associated virus (AAV) entry is determined by its interactions with specific surface
glycans and a proteinaceous receptor (s). Adeno-associated virus receptor (AAVR)(also …

Microglia have emerged as a critical component of neurodegenerative diseases. Genetic
manipulation of microglia can elucidate their functional impact in disease. In neuroscience …

Adeno-associated virus (AAV) capsid libraries have generated improved transgene delivery
vectors. We designed an AAV library construct, iTransduce, that combines a peptide library …

Adeno-associated virus (AAV) has been successfully used to deliver gene therapy to
improve auditory function in mouse models of hereditary hearing loss. Many forms of …

Background Multiple genetic modifications may be required to develop potent off-the-shelf
chimeric antigen receptor (CAR) T cell therapies. Conventional CRISPR-Cas nucleases …